Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 vs 6 months of FOLFOX or XELOX in colon cancer (HORG)
NCT01308086Phase 3Unknown
- Sponsor
- Hellenic Oncology Research Group
- Start
- Oct 2010
- Primary completion
- Nov 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, fluorouracil, folinic acid, capecitabine in colon cancer, rectal cancer, sponsored by Hellenic Oncology Research Group. Status: unknown.
02
Drugs
oxaliplatinfluorouracilfolinic acidcapecitabine
03
Conditions
colon cancerrectal cancer
Beyond the preview
Go deeper on NCT01308086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308086.